Can You Take MOTS-c With Tirzepatide or Semaglutide?

The medications this page covers:

Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices because they are priced by dose. Compounded medications are not FDA approved.

Different jobs

Tirzepatide is a single peptide that activates two incretin receptors. It acts on appetite centres in the brain, slows gastric emptying and changes insulin and glucagon signalling, and the weight change reported in its trials follows from people eating less over a long period. It is not a stimulant and does not force the body to burn anything. See what is tirzepatide.

MOTS-c is a 16-amino-acid peptide encoded in the mitochondria's own DNA, identified in a 2015 paper in Cell Metabolism. In cells it slows the folate cycle, a by-product called AICAR builds up, and AICAR activates AMPK, the same low-fuel sensor exercise switches on. Skeletal muscle appeared to be the main target. It is not a GLP-1 medication, not a stimulant, not a growth hormone secretagogue, and does not work through appetite. See what is MOTS-c.

The reason behind the pairing

Weight lost on a GLP-1 is not all fat. In the STEP 1 body-composition substudy of semaglutide, both fat mass and lean mass fell, though fat fell by more. Appetite suppression this strong also makes under-eating protein the default. Most adjuncts to a GLP-1 are prescribed with that gap in mind, and MOTS-c's place is muscle fuel handling: prescribers describe subtle changes such as better training tolerance and steadier afternoon energy. That is a mechanism and clinical experience, not a trial result. Protein and resistance training remain the countermeasures with the most behind them.

MOTS-c is more often prescribed inside a blend than alone, and several blends are commonly used alongside tirzepatide or semaglutide.

• PHYSIQ combines it with tesamorelin, ipamorelin and AOD-9604. Growth hormone reduces insulin sensitivity while GLP-1 medications act in the other direction, so glucose is watched for anyone taking a tesamorelin blend with a GLP-1.
• SHRED combines it with AOD-9604, CJC-1295 and ipamorelin. Ipamorelin acts at the receptor ghrelin uses to signal hunger, so some people notice more appetite rather than less.
• FUSION combines it with BPC-157, 5-Amino-1MQ and tesamorelin, and is positioned for use with or without a GLP-1. Prescribers using FUSION alongside a GLP-1 describe less of the gut discomfort patients associate with the GLP-1; that has not been tested in a trial.

Never take MOTS-c alone on top of a blend that already contains it without your physician knowing; that changes the dose without anyone having decided it should change. Comparisons are in MOTS-c vs tesamorelin and MOTS-c vs SLU-PP-332 vs 5-Amino-1MQ.

The schedules are independent. Use a separate fresh syringe for each and never draw both into one. Dosing detail is in MOTS-c dosage and tirzepatide dosing chart.

Tested athletes

MOTS-c is on the WADA Prohibited List at all times as an AMPK activator, and USADA has stated it is not eligible for a therapeutic use exemption. A GLP-1 does not change that.

Everything above applies to semaglutide. It acts at the GLP-1 receptor only, where tirzepatide acts at two, but it reduces appetite and slows gastric emptying in the same way, rarely causes low blood sugar on its own, and carries a small average rise in resting heart rate on its label. MOTS-c is doing the same different job alongside it. Semaglutide and tirzepatide are never taken together. See semaglutide vs tirzepatide.

There are no randomised controlled trials of MOTS-c in humans. Its evidence is mouse and cell work, plus observational human studies of the body's own MOTS-c, which rises with exercise in muscle and blood. A 2021 paper in Nature Communications reported better physical performance in treated mice and the exercise rise in people. None of that tests injected MOTS-c in people, and none of it tests MOTS-c with a GLP-1.

On regulation, the FDA removed MOTS-c from Category 2 of its interim 503A list on 15 April 2026, and its compounding advisory committee voted 7 to 5, with two abstentions, on 23 July 2026 to recommend adding it to the 503A Bulks List. The FDA's final determination is pending.

So the honest statement is narrow. Tirzepatide has the evidence for weight; MOTS-c has a coherent preclinical story about muscle fuel handling; the two are commonly prescribed together; and no trial shows the pairing works better than tirzepatide alone. More is in MOTS-c benefits, MOTS-c side effects and what peptides can you take with tirzepatide.

1. Name the gap. "My training has stalled and I am worried about muscle" gives your physician more to work with than a product name.
2. List every glucose-lowering medication. Insulin and sulfonylureas especially.
3. Let your physician check for duplication. PHYSIQ, SHRED, FUSION, SYNAPSE and EUPHORIA all contain MOTS-c.
4. Start one thing at a time, and report what happens. Including nothing.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and your directions printed on the vial.
5. Your care team stays reachable for side effects and questions. Refills run every 28 days, one vial per fill.

Pepti is cash-pay and does not bill insurance. Step-by-step pages: how to get MOTS-c prescribed online and how to get tirzepatide prescribed online.